Translational Development Acquisition Corp.(NASDAQ) TDACU

Market Cap$233.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+21%
5 YearN/A
1 Year+16%
1 Month-4%
$12.11
+0.00%
+0.00Today
Translational Development Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 12.112026-10-02
Translational Development Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.66%USD 12.572026-09-23
1 month-3.66%USD 12.572026-08-25
3 month+6.88%USD 11.332026-07-02
Year to date+16%USD 10.442025-12-15
1 year+15.77%USD 10.462025-09-26
Since inception+20.98%USD 10.012024-12-23

Translational Development Acquisition Corp. Financials at a Glance

Market Cap

$233.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$5.54

EPS (TTM)

$0.25

P/E Ratio

47.77

Dividend

$0.00

Beta (Volatility)

0.18 (Low)

Price

$12.11

Volume

2

Open

$12.65

Previous Close

$12.11

Daily Range

$12.11 - $12.65

52-Week Range

$10.44 - $17.29

Estimated Earnings Date

N/A

TDACU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY.

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Michael B. Hoffman, MBA

Website

www.translational-development.com

TDACU Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

3.44%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.09%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$233.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.31M

Volume

2

Avg. Volume

53.662

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Translational Development Acquisition Corp. Performance Analysis

Translational Development Acquisition Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Translational Development Acquisition Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00N/A
20232023-12-31USD -0.03920.0%
20242024-12-31USD -0.00-87.5%
20252025-12-31USD 0.29N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$233.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$123.89

N/A

Employees

2

N/A

Net Income

$0.95

+0.6%

EBITDA

-$0.66

+3.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.19

+3263.7%

Total Debt

$1.10

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.10

N/A

Return on Assets

3.30%

N/A

Return on Invested Capital

78.08%

+0.8%

Free Cash Flow

-$0.34

+2.0%

Operating Cash Flow

-$0.34

+2.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About TDACU

What is the current price of Translational Development Acquisition Corp.?

Translational Development Acquisition Corp. is trading at $12.11 per share.

What is the 52-week range for Translational Development Acquisition Corp.?

Over the past 52 weeks, Translational Development Acquisition Corp. has traded between $10.44 and $17.29.

How much debt does Translational Development Acquisition Corp. have?

As of the most recent reporting period, Translational Development Acquisition Corp. reported total debt of $1.10M.

How much cash does Translational Development Acquisition Corp. have on hand?

Translational Development Acquisition Corp. reported $85.88K in cash and cash equivalents in its most recent financial results.

What is Translational Development Acquisition Corp.’s dividend yield?

Translational Development Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services